We will review, in alphabetical order, adenoid cystic carcinoma (NFIB and MYB fusion), mixed tumor (PLAG1 fusion), cylindroma and spiradenoma (NF-κB activation through CYLD inactivation or ALKP1 hotspot mutation), hidradenoma (CRTC1/3 and MAML2 fusion), myoepithelioma (EWSR1 and FUS fusion), poroma (YAP1 and NUTM1 fusion), secretory carcinoma (ETV6 and NTRK3 fusion), tubular adenoma and syringocystadenoma papilliferum (HRAS and BRAF activating mutations). The gene discussed is NFIB; the disease is benign spiradenoma.